UNITED STATES SECURITIES AND EXCHANGE COMMISSION JUNE 19, 2013

ORDER GRANTING CONFIDENTIAL TREATMENT UNDER THE SECURITIES ACT OF 1933

PTC Therapeutics, Inc.

File No. 333-188657 - CF#29488

PTC Therapeutics, Inc. submitted an application under Rule 406 requesting confidential treatment for information it excluded from the Exhibits to a Form S-1 registration statement filed on May 16, 2013, as amended.

Based on representations by PTC Therapeutics, Inc. that this information qualifies as confidential commercial or financial information under the Freedom of Information Act, 5 U.S.C. 552(b)(4), the Division of Corporation Finance has determined not to publicly disclose it. Accordingly, excluded information from the following exhibits will not be released to the public for the time periods specified:

Exhibit 10.14	through November 23, 2016
Exhibit 10.15	through March 18, 2023
Exhibit 10.16	through March 18, 2023
Exhibit 10.17	through March 18, 2023

For the Commission, by the Division of Corporation Finance, pursuant to delegated authority:

Elizabeth M. Murphy Secretary